|
|
Melanoma Care Options™ Issue 1: Pathogenesis and Predictors of Prognosis in Melanoma 1. Interested in reading the publication and earning CME credits online? Click here to register, click here to download the publication and click here to take the CME test and evaluation on line. 2. Just want to download the publication? Click here to download the publication. You can always print out and fax the CME information to us later. Continuing Medical Education Information Instructions for Participation:
To receive a maximum of 1.5 AMA PRA Category 1 Credits™ (or 1.5 CNE credits) for this activity:
To receive up to 1.5 CNE credits for this activity:
Target Audience This activity is directed toward surgical oncologists, oncology nurses, medical oncologists, dermatologists, and other health care professionals who treat or screen for melanoma. Statement of Need Management of all stages of melanoma requires a concerted effort on the part of several specially trained members of a healthcare team. Assessing risk, getting patients into the healthcare system, evaluating prognostic information, analyzing and interpreting new therapeutic information and choosing appropriate therapy, working as a team, and educating, guiding, and motivating the patient remain challenging. A core group of specialists are knowledgeable about the optimal management of this malignancy, and this activity provides their insight for practicing healthcare providers. Learning Objectives: After completing this activity, the participants will be able to:
Accreditation and Credit Designation The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™". Each physician should claim only those credits commensurate with the extent of his or her participation in the activity. 1.5 contact hours of Continuing Nursing Education will be granted by the University of Pittsburgh Medical Center. The University of Pittsburgh Medical Center is an approved provider of continuing nursing education by the Pennsylvania State Nurses Association (PSNA), an accredited approver by the American Nurses Credentialing Center s Commission on Accreditation. We gratefully acknowledge an educational grant from Schering-Plough Corporation in support of this activity. Contributing Authors and Disclosures Mohammed Kashani-Sabet, MD Professor of Dermatology Director, Melanoma Center UCSF Cancer Center University of California San Francisco School of Medicine San Francisco, CA Consultant: Chiron, Schering-Plough Corporation Speaker�s Bureau: Chiron, Schering-Plough Corporation Stockholder: Melanoma Diagnostics Sancy Leachman, MD, PhD Associate Professor of Dermatology University of Utah Health Sciences Center Director, Melanoma and Cutaneous Oncology Huntsman Cancer Institute Salt Lake City, UT Speaker�s Bureau: Myriad Genetics Jane L. Messina, MD Professor, Departments of Pathology and Cell Biology and Dermatology University of South Florida College of Medicine Staff Dermatopathologist, Cutaneous Oncology Program H. Lee Moffitt Cancer Center Tampa, FL No financial relationships to disclose Vernon K. Sondak, MD Chief, Department of Cutaneous Oncology Director of Surgical Education H. Lee Moffitt Cancer Center Tampa, FL Speaker�s Bureau: Schering-Plough Corporation, Pfizer Inc. Susan M. Swetter, MD Associate Professor of Dermatology Director, Pigmented Lesion and Melanoma Program Stanford University Medical Center/VA Palo Alto Health Care System Stanford, CA Grant/Research Support: Schering-Plough Corporation Date of Original Release: January 15, 2009
|
|
 |
||||||||||||||||
